摘要
通过血清代谢组学分析半夏白术天麻汤(Banxia Baizhu Tianma decoction,BBT)干预正常高值血压(prehypertension,PHT)痰湿壅盛证大鼠血清生物内源性物质的变化,明确BBT的代谢调控途径。复制正常高值血痰湿壅盛证大鼠模型,采集大鼠的血压、行为学指标、血清生化指标,评估BBT的调节血压和血脂的药效,利用超高效液相色谱-四极杆/静电场轨道阱高分辨质谱联用(UPLC-Q-orbitrap-MS)代谢组学技术,测定大鼠血清中内源性小分子物质变化,寻找潜在的生物标志物。结果显示,BBT可以对其中9个代谢物进行调控,主要包括花生四烯酸、胆酸、甘脱氧胆酸、N-腺苷酪氨酸、精氨酸、溶血磷脂酰乙醇胺(20:0/0:0)、溶血磷脂(P-18:0)、溶血磷脂(18:0)、溶血磷脂[22:5(7Z,10Z,13Z,16Z,19Z)]。通过MetaboAnalyst进行代谢通路分析,共有7条代谢通路与大鼠血压的改变密切相关,其中花生四烯酸代谢通路最为关键。模型大鼠体内代谢差异物有向正常水平回调的趋势,从代谢组学角度为BBT的作用机制提供了研究依据。本研究已获得山东中医药大学实验动物福利伦理审查委员会批准(批准号:SDUTCM20211103001)。
The alterations of serum biological endogenous chemicals in rats with phlegm dampness accumulation syndrome of prehypertension(PHT)were interfered by Banxia Baizhu Tianma decoction(BBT),and the metabolic regulatory pathway of BBT was clarified using serum metabonomics analysis.To replicate the rat model of prehypertension phlegm dampness syndrome,blood pressure,behavioral markers,and serum biochemical markers of rats were collected.BBT's effectiveness in controlling blood pressure and blood lipids was assessed,and changes in endogenous small molecules in rat serum were determined using UPLC-Q-Orbitrap MS metabolic analysis.The results showed that BBT could regulate 9 metabolites,including arachidonic acid,cholic acid,glycodeoxycholic acid,N-adenosyltyrosine,arginine,lysophosphatidylethanolamine(20:0/0:00),lysophospholipid(P-18:0),lysophospholipid(18:0),lysophospholipid(22:5(7Z,10Z,13Z,16Z,19Z)).MetaboAnalyst was used to analyze the metabolic pathway.There were 7 metabolic pathways closely related to the change of blood pressure in rats,among which arachidonic acid metabolic pathway was the most critical.The metabolism difference foreign body in the model rats tends to return to the normal level,which provides a research basis for the mechanism of BBT from the perspective of metabonomics.This study was approved by the Experimental Animal Welfare Ethics Review Committee of Shandong University of Traditional Chinese Medicine(approval number:SDUTCM20211103001).
作者
叶建桥
郭晓庆
李淑敏
蒋海强
齐冬梅
齐于辰
YE Jian-qiao;GUO Xiao-qing;LI Shu-min;JIANG Hai-qiang;QI Dong-mei;QI Yu-chen(Institute of Innovation in Traditional Chinese Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Experimental Center,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Shandong Provincial Key Laboratory of Traditional Chinese Medicine for Basic Research,Jinan 250355,China;Key Laboratory of Traditional Chinese Medicine Classical Theory,Ministry of Education,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Faculty of Health,Shandong University of Traditional Chinese Medicine,Jinan 250355,China)
出处
《药学学报》
CAS
CSCD
北大核心
2023年第7期1822-1832,共11页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81974555).
